|
The icd was received for analysis.Prior to the analysis of the device, the quality documents accompanying the manufacturing process for this icd were re-investigated and all production steps were performed accordingly.Particularly the final acceptance test proved the device functions to be as specified.The ability of the device to deliver therapies was verified.The anti-bradycardia pacing pulses proved to be normal and in amplitude and frequency as programmed.A fibrillation signal was applied, and the device delivered a defibrillation shock as specified, documenting a normal and expected sensing and shock delivery.In particular, the specified energy level was reached.At a next step the memory content of the device was inspected.The data showed an inconsistency between the amount of charge taken from the battery and the battery voltage, which led to the automatic activation of the eri battery status.The data analysis confirmed an unexpectedly low battery voltage.Therefore, the device was opened, and the inner assembly was inspected.The visual inspection of the inner assembly showed no anomalies.The overall current consumption of the electrical module was directly measured and proved to be normal and as expected.The battery was sent to the manufacturer for further analysis.The manufacturing records of the battery were inspected, documenting that the battery parameters were within specification during the battery manufacturing.No anomalies were documented during the production process, associated with this battery.The battery was subjected to a visual inspection which did not reveal any signs of damage.In a next step, the battery was opened for destructive analysis.The inspection of the inner assembly identified a short circuit, which led to the elevated internal self-depletion.In conclusion, the analysis revealed an elevated internal self-depletion within the battery.Based on the analysis all therapy functions of the device were entirely available while the device was implanted and in service.
|